The place of metabolic agents in the management of stable angina pectoris.
The treatment of stable angina should aim to relieve symptoms and in at-risk cases prolong life. Medical therapy, PTCA and CABG should be seen as complementary, not competitive, strategies. Optimal utilization of all three treatment modalities either alone or in combination can provide substantial and sustained symptomatic relief for angina patients. Metabolic agents such as Trimetazidine by acting at the cellular level and not influencing heart rate or blood pressure have a useful and unique role to play in addition to conventional haemodynamic agents such as the betablockers or calcium antagonists. This review looks at the role of trimetazidine as part of the overall management of the stable angina patient.
Jackson
G
G
Cardiothoracic Centre, St. Thomas' Hospital, London.
D000787:Angina Pectoris / Q000188:drug therapy* / Q000378:metabolism; D015906:Angioplasty, Balloon, Coronary; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D006801:Humans; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic
D002317:Cardiovascular Agents